![]() ACS journals are among the most cited, most trusted and most read within the scientific literature however, ACS itself does not conduct chemical research. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. ![]() The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Ventus is also pursuing a broad pipeline of additional targets, as its platform capabilities open opportunities across a wide range of therapeutic applications. The company is currently developing drugs for three targets, including NLRP3, a well-established but difficult-to-target driver of many chronic inflammatory and immune-related diseases. The company’s advanced proprietary computational chemistry tools and structure-based modeling allow rational design of medicines for therapeutic targets in the inflammasome and nucleic acid sensing signaling pathways. Using its Structural Immunology platform, Ventus scientists apply disruptive technologies to generate and express stable monomers of therapeutic targets of interest, and to elucidate their protein structures. “This defines our mission at Ventus, as we work to apply our platform to pioneer new ways to develop transformative medicines for patients.” We are honored to be recognized as one of the 10 Start-Ups to Watch by C&E News and to have our Structural Immunology platform highlighted as a groundbreaking approach to unravel the potential of many innate immunity targets,” said Marcelo Bigal, M.D., Ph.D., president and CEO of Ventus. “Diseases mediated by dysfunction of innate immunity cause an extraordinary burden to patients and their families, but most drug targets of interest in this field have been elusive for discovering new medicines. Ventus was selected by C&E News based on the company’s proprietary Structural Immunology platform, which enables the pursuit of previously intractable drug targets for autoimmune diseases, inflammatory diseases and cancer. Ĭhemical & Engineering News ( C&E News), the weekly newsmagazine of the American Chemical Society (ACS), selects its annual list of 10 chemistry start-ups to watch from among hundreds of nominations submitted from readers around the world and those compiled by the magazine’s writers and editors, who scoured the chemical, biotech and materials world for young companies with great promise. & MONTREAL, Novem– Ventus Therapeutics, a biopharmaceutical company with proprietary technologies for structure-enabled small-molecule drug discovery that is developing medicines targeting the innate immune system, announced today that it has been selected as one of 10 Start-Ups to Watch by Chemical & Engineering News.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |